US2005271670A1PendingUtilityA1

Treatments for cancer

54
Individually held — no corporate assignee on recordPriority: Apr 28, 2004Filed: Apr 28, 2005Published: Dec 8, 2005
Est. expiryApr 28, 2024(expired)· nominal 20-yr term from priority
Inventors:Suzanne M. SpongThomas B. NeffStephen J. Klaus
A61K 39/395A61K 2039/505A61K 45/06A61P 35/00G01N 2333/475C07K 16/22A61K 39/39558C07K 14/71G01N 33/57525
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing pancreatic tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF), and methods for identifying such agents.

Claims

exact text as granted — not AI-modified
1 . A method for identifying an agent that inhibits anchorage-independent cell growth, the method comprising: 
 (a) culturing MIA PaCa-2 cells, wherein the cells have been modified to express connective tissue growth factor (CTGF), with an agent under conditions suitable, in the absence of the agent, for anchorage-independent cell growth;    (b) measuring the amount of cell growth that occurs in the presence of the agent; and    (c) comparing the amount of cell growth that occurs in the presence of the agent with the amount of cell growth that occurs in the absence of the agent, wherein a decrease in the amount of cell growth in the presence of the agent relative to the amount of cell growth that occurs in the absence of the agent is indicative of an agent that inhibits anchorage-independent cell growth.    
   
   
       2 . The method of  claim 1 , wherein the CTGF is human CTGF.  
   
   
       3 . The method of  claim 1 , wherein the MIA PaCa-2 cells secrete at least about 0.3 μg CTGF/10 5  cells/48 hrs.  
   
   
       4 . The method of  claim 1 , wherein the measuring the amount of cell growth comprises counting clusters of cells.  
   
   
       5 . The method of  claim 1 , wherein the culturing comprises dispersing the cells in a semi-solid support medium appropriate for anchorage-independent cell growth.  
   
   
       6 . The method of  claim 5 , wherein the semi-solid support medium comprises about 0.35% agar.  
   
   
       7 . A method for reducing metastasis of a tumor in a subject, the method comprising administering to the subject an agent identified by the screening assay of  claim 1 , thereby reducing metastasis of the tumor.  
   
   
       8 . The method of  claim 7 , wherein the tumor is a pancreatic tumor.  
   
   
       9 . A method for reducing expansion of a pancreatic tumor in a subject, the method comprising administering to the subject an agent identified by the method of  claim 1 , thereby reducing expansion of the pancreatic tumor.  
   
   
       10 . A method for reducing pancreatic tumor cell survival in a subject, the method comprising administering to the subject an agent identified by the method of  claim 1 , thereby reducing pancreatic tumor cell survival.  
   
   
       11 . A method for reducing metastasis of a tumor in a subject, the method comprising administering to the subject an agent that inhibits CTGF activity, thereby reducing metastasis of the tumor.  
   
   
       12 . The method of  claim 11 , wherein the tumor is a pancreatic tumor.  
   
   
       13 . A method for reducing progression of cancer in a subject, the method comprising administering to the subject an agent that reduces metastasis of a tumor and that reduces at least one process selected from the group consisting of tumor expansion and tumor cell survival, thereby reducing progression of cancer in the subject.  
   
   
       14 . The method of  claim 13 , wherein the tumor is a pancreatic tumor.  
   
   
       15 . A method for reducing metastasis of a pancreatic tumor in a subject, the method comprising administering to the subject an agent that inhibits CTGF activity, thereby reducing metastasis of the pancreatic tumor.  
   
   
       16 . A method for reducing pancreatic tumor cell survival in a subject, the method comprising administering to the subject an agent that inhibits CTGF activity, thereby reducing pancreatic tumor cell survival.  
   
   
       17 . A method for reducing pancreatic tumor survival in a subject, the method comprising administering to the subject an agent that inhibits CTGF activity, thereby reducing pancreatic tumor survival.  
   
   
       18 . A method for reducing pancreatic tumor expansion in a subject, the method comprising administering to the subject an agent that inhibits CTGF activity, thereby reducing pancreatic tumor expansion.  
   
   
       19 . The method of  claim 11 , wherein the tumor is an adenocarcinoma.  
   
   
       20 . The method of  claim 19 , wherein the adenocarcinoma is a ductal adenocarcinoma.  
   
   
       21 . The method of  claim 11 , wherein the agent is an oligonucleotide that specifically binds to a polynucleotide encoding CTGF.  
   
   
       22 . The method of  claim 11 , wherein the agent is an antibody that specifically binds to CTGF.  
   
   
       23 . The method of  claim 22 , wherein the antibody is a monoclonal antibody or an active fragment thereof.  
   
   
       24 . The method of  claim 23 , wherein the antibody is CLN-1 or any derivative thereof.  
   
   
       25 . The method of  claim 11 , wherein the agent is a small molecule.  
   
   
       26 . The method of  claim 11 , wherein the agent is an aptamer.  
   
   
       27 . The method of  claim 11 , wherein a cytotoxic chemotherapeutic agent is also administered to the subject.  
   
   
       28 . The method of  claim 11 , wherein the subject is a mammal.  
   
   
       29 . The method of  claim 28 , wherein the mammal is a human.

Join the waitlist — get patent alerts

Track US2005271670A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.